{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:59Z","timestamp":1794048899066,"version":"4.8.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jhep.2019.11.003","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T06:02:46Z","timestamp":1573538566000},"page":"539-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":318,"title":["Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021"],"prefix":"10.1016","volume":"72","author":[{"given":"Markus","family":"Cornberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Suk-Fong","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia R.","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong-Mi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Dandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schlottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.11.003_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Taormina Workshop on Occult HBVIFM. Update of the statements on biology and clinical impact of occult hepatitis b virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib4","doi-asserted-by":"crossref","first-page":"e3565","DOI":"10.1097\/MD.0000000000003565","article-title":"Relationship between hepatic steatosis and the elevation of aminotransferases in HBV-infected patients with HBe-antigen negativity and a low viral load","volume":"95","author":"Enomoto","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2019.11.003_bib5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cgh.2017.01.032","article-title":"Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy","volume":"15","author":"Jacobson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib6","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2019.11.003_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.11.003_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jvh.12927","article-title":"Comparison of overall survival between antiviral-induced viral suppression and inactive\u00a0phase chronic hepatitis B patients","volume":"25","author":"Cho","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.003_bib11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2019.11.003_bib12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib14","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2019.11.003_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/gutjnl-2013-306221","article-title":"HBsAg seroclearance with NUCs: rare but important","volume":"63","author":"Cornberg","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2019.11.003_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting innate and adaptive immune responses to cure chronic HBV infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.08.008","article-title":"Immune-modulators to combat hepatitis B virus infection: from IFN-alpha to novel investigational immunotherapeutic strategies","volume":"122","author":"Isorce","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2019.11.003_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bpg.2008.11.007","article-title":"Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues","volume":"22","author":"Buster","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2019.11.003_bib21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jvh.12738","article-title":"HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up","volume":"24","author":"Stelma","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.003_bib22","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","author":"Yip","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jvh.12993","article-title":"New viral biomarkers for hepatitis B: are we able to change practice?","volume":"25","author":"Honer Zu Siederdissen","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.003_bib25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/apt.14636","article-title":"Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection","volume":"47","author":"Kuhnhenn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib26","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JCM.00726-13","article-title":"Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance","volume":"51","author":"Shinkai","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2019.11.003_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","article-title":"An ultra-sensitive Abbott ARCHITECT((R)) assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"105","author":"Lou","year":"2018","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2019.11.003_bib28","doi-asserted-by":"crossref","first-page":"e22334","DOI":"10.1002\/jcla.22334","article-title":"Evaluation of the highly sensitive chemiluminescent enzyme immunoassay \u201cLumipulse HBsAg-HQ\u201d for hepatitis B virus screening","volume":"32","author":"Deguchi","year":"2018","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1016\/j.jhep.2019.11.003_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","article-title":"Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2019.11.003_bib31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib33","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","author":"Wang","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib35","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2019.11.003_bib36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2019.11.003_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib39","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1016\/S0618-8278(19)30904-1","article-title":"Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?","volume":"70","author":"Carey","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib40","doi-asserted-by":"crossref","first-page":"e0130209","DOI":"10.1371\/journal.pone.0130209","article-title":"Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease","volume":"10","author":"Yuan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.11.003_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection","volume":"69","author":"Yang","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib42","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/513296","article-title":"The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg","volume":"44","author":"Gerlich","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.003_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP3014","article-title":"ImPortance of IP-10 in hepatitis B","volume":"21","author":"Cornberg","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib44","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib47","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP3304","article-title":"Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data","volume":"24","author":"Pavlovic","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase II trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.003_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib54","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib56","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"Honer Zu Siederdissen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.003_bib57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.11.003_bib58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hep.29821","article-title":"Less can be more: a finite treatment approach for HBeAg-negative chronic hepatitis B","volume":"68","author":"Lampertico","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib60","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry\u00a0of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib62","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2019.11.003_bib63","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2019.11.003_bib64","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1016\/S0618-8278(19)30086-6","article-title":"A\u00a0first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver","volume":"70","author":"Wang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib65","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2019.11.003_bib66","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis B virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2019.11.003_bib67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2019.11.003_bib68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsiere","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2019.11.003_bib69","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30491","article-title":"Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus","volume":"69","author":"Sekiba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtn.2018.02.005","article-title":"Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in\u00a0vivo","volume":"11","author":"Javanbakht","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2019.11.003_bib72","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A\u00a0randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jhep.2019.11.003_bib73","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1016\/S0618-8278(19)30092-1","article-title":"Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU\/ml threshold","volume":"70","author":"Yuen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib74","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.8b01245","article-title":"Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action","volume":"61","author":"Han","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2019.11.003_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2017.11.009","article-title":"HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element","volume":"149","author":"Zhou","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2019.11.003_bib76","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","article-title":"A\u00a0novel orally available small molecule that inhibits hepatitis B virus expression","volume":"68","author":"Mueller","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","article-title":"Hepatitis B core protein as a therapeutic target","volume":"21","author":"Mak","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jhep.2019.11.003_bib78","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib79","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib80","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.11.003_bib81","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1016\/S0168-8278(18)31283-2","article-title":"Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a","volume":"68","author":"Vaillant","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib82","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase II trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib83","doi-asserted-by":"crossref","first-page":"e1005788","DOI":"10.1371\/journal.ppat.1005788","article-title":"Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in\u00a0vivo","volume":"12","author":"Gill","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2019.11.003_bib84","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib85","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib86","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib88","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib89","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.04321-14","article-title":"STING agonists induce an innate antiviral immune response against hepatitis B virus","volume":"59","author":"Guo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2019.11.003_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2019.11.003_bib91","doi-asserted-by":"crossref","first-page":"e0161313","DOI":"10.1371\/journal.pone.0161313","article-title":"Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B","volume":"11","author":"Korolowicz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.11.003_bib92","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1016\/S0618-8278(19)30084-2","article-title":"Ascending dose cohort study of inarigivir - a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial","volume":"70","author":"Yuen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib93","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib94","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jhep.2019.02.016","article-title":"OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection","volume":"70","author":"Jacobi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib95","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in\u00a0vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2019.11.003_bib96","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(17)30315-X","article-title":"A\u00a0phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients","volume":"66","author":"Gane","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib97","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13085","article-title":"Therapeutic vaccination for chronic hepatitis B: a systematic review and meta-analysis","author":"Lim","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.003_bib98","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.003_bib99","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jcyt.2017.07.011","article-title":"T-cell therapy for chronic viral hepatitis","volume":"19","author":"Bertoletti","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jhep.2019.11.003_bib101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T\u00a0cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.11.003_bib102","article-title":"T\u00a0cell receptor grafting allows virological control of Hepatitis B virus infection","volume":"130","author":"Wisskirchen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2019.11.003_bib103","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2019.11.003_bib104","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.11.003_bib105","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s40264-014-0186-3","article-title":"Liver safety assessment in special populations (hepatitis B, C, and oncology trials)","volume":"37","author":"Kullak-Ublick","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2019.11.003_bib106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib107","doi-asserted-by":"crossref","first-page":"k698","DOI":"10.1136\/bmj.k698","article-title":"Key design considerations for adaptive clinical trials: a primer for clinicians","volume":"360","author":"Thorlund","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2019.11.003_bib108","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2019.11.003_bib109","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bpg.2017.04.007","article-title":"Treatment of hepatitis B virus with combination therapy now and in the future","volume":"31","author":"Emery","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2019.11.003_bib110","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib111","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib112","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"Shimura","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib113","doi-asserted-by":"crossref","first-page":"E464","DOI":"10.1016\/S0618-8278(19)30916-8","article-title":"A\u00a0phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431","volume":"70","author":"Armas","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib114","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/hep4.1339","article-title":"A\u00a0pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B","volume":"3","author":"Rossignol","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2019.11.003_bib115","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0168-8278(18)30254-X","article-title":"Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered siRNA agent in preclinical models","volume":"68","author":"Lee","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib116","first-page":"224a","article-title":"GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in\u00a0vitro and in\u00a0vivo","volume":"62","author":"Sepp-Lorenzino","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib117","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0168-8278(18)30252-6","article-title":"Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer","volume":"68","author":"Mani","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib118","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1016\/S0618-8278(19)30230-0","article-title":"Interim safety and efficacy results of the ABI-H0731 phase IIa program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients","volume":"70","author":"Ma","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib119","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1016\/S0618-8278(19)30964-8","article-title":"RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients","volume":"70","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib120","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1016\/S0618-8278(19)30258-0","article-title":"Phase Ia study of the safety, tolerability and pharmacokinetics of ABI-H2158, a novel second-generation HBV core inhibitor, in healthy volunteers","volume":"70","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib121","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1016\/S0618-8278(19)30085-4","article-title":"Preclinical profile of HBV core protein inhibitor, ABI-H3733, a potent inhibitor of cccDNA generation in HBV infected cells","volume":"70","author":"Huang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib122","doi-asserted-by":"crossref","first-page":"E457","DOI":"10.1016\/S0618-8278(19)30902-8","article-title":"Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation","volume":"70","author":"Bassit","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib123","doi-asserted-by":"crossref","first-page":"E474","DOI":"10.1016\/S0618-8278(19)30936-3","article-title":"EDP-514, a novel HBV core inhibitor with potent antiviral activity both in\u00a0vitro and in\u00a0vivo","volume":"70","author":"Vaine","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib124","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(17)30317-3","article-title":"Multiple dose study of GLS4JHS, interfering with the assembly of hepatitis B virus core particles, in patients infected with hepatitis B virus","volume":"66","author":"Ding","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.12_12922","article-title":"Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model","volume":"25","author":"Gao","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.003_bib126","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","article-title":"Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism","volume":"68","author":"Niu","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib127","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1016\/S0618-8278(19)30088-X","article-title":"Antiviral activity of JNJ-4964 (AL-034\/TQ-A3334), a selective toll-like receptor 7 agonist, in AAV\/HBV mice after oral administration for 12 weeks","volume":"70","author":"Herschke","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib128","first-page":"238a","article-title":"Safety, pharmacokinetics and pharmacodynamics of oral TLR8 agonist GS-9688 in patients with chronic hepatitis B: a randomized, placebo-controlled, double-blind phase Ib study","volume":"68","author":"Gane","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib129","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1016\/S0618-8278(19)30944-2","article-title":"First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis","volume":"70","author":"Addy","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/21645515.2018.1433970","article-title":"A\u00a0meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model","volume":"14","author":"Kratzer","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhep.2019.11.003_bib131","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/S0618-8278(19)30271-3","article-title":"A\u00a0phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b (chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study","volume":"70","author":"Hu","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib132","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1016\/S0618-8278(19)30907-7","article-title":"Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice","volume":"70","author":"Cargill","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib133","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1016\/S0618-8278(19)30090-8","article-title":"A\u00a0phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection","volume":"70","author":"Lim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib134","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase IIb clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib136","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase II clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.11.003_bib137","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase IIA trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.003_bib138","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.003_bib139","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:37:26Z","timestamp":1759174646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0168827819306713"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736916185.793579967","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver and American Association for the Study of Liver Diseases. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}